News Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
6.32 ^USD	-0.78%		-9.20%	-29.70%

Apr. 03	Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	CI
Mar. 28	North American Morning Briefing : Stocks Set for -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International	Apr. 04	GL
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association	Apr. 03	GL
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	Apr. 03	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 13	GL
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 13	AQ
Transcript : Travere Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM	Mar. 12
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy	Mar. 11	MT
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)	Mar. 11	GL
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy	Mar. 11	CI
Travere Therapeutics to Present at Upcoming Investor Conferences	Feb. 26	GL
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy	Feb. 26	AQ
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease	Feb. 23	MT
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy	Feb. 23	GL
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy	Feb. 23	CI
Travere drug for rare kidney condition recommended for EU approval	Feb. 23	RE
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy	Feb. 23	PR
Transcript : Travere Therapeutics, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $45.1M, vs. Street Est of $41.8M	Feb. 15	MT
Travere: Q4 Earnings Snapshot	Feb. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Summary

Filters